Literature DB >> 12714786

GH values after clonidine stimulation measured by immunofluorometric assay in normal prepubertal children and GH-deficient patients.

Eveline G P Silva1, Natasha Slhessarenko, Ivo J P Arnhold, Marcelo C Batista, Vivian Estefan, Maria G F Osorio, Suemi Marui, Berenice B Mendonca.   

Abstract

OBJECTIVE: To establish the cut-off values of GH measured by immunofluorometric assay, a more sensitive and specific assay, in normal prepubertal children and compare their values with those of proven GH-deficient patients.
METHODS: 30 normal children (20 males) and 26 patients with known causes of GH deficiency were submitted to the clonidine test and their GH values were compared. A powdered clonidine tablet (0.1 mg/m(2)) was given orally and blood samples for GH measurements were drawn at times -30, 0, 60, 90 and 120 min.
RESULTS: GH peak values presented a wide variation ranging from 1.7 to 25 micro g/l (mean +/- SD = 12.87 +/- 5.8 micro g/l) in the normal group. The cut-off values for the 5th and 10th percentiles of the distribution curve were 3.3 and 5.5 micro g/l, respectively. In the GH deficiency group, maximum GH levels after clonidine stimulation ranged from <0.1 to 2.1 micro g/l (0.56 +/- 0.58 micro g/l).
CONCLUSIONS: The cut-off values obtained with the immunofluorometric method are lower than the ones obtained by radioimmunoassay. We suggest a cut-off value of 3.3 micro g/l (5th percentile) that ensures 100% of sensitivity along with 93% of specificity to exclude the diagnosis of GH deficiency when using this immunofluorometric method. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12714786     DOI: 10.1159/000070222

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  6 in total

1.  Frequent development of combined pituitary hormone deficiency in patients initially diagnosed as isolated growth hormone deficiency: a long term follow-up of patients from a single center.

Authors:  Aline P Otto; Marcela M França; Fernanda A Correa; Everlayny F Costalonga; Claudia C Leite; Berenice B Mendonca; Ivo J P Arnhold; Luciani R S Carvalho; Alexander A L Jorge
Journal:  Pituitary       Date:  2015-08       Impact factor: 4.107

2.  Clonidine and glucagon stimulation for testing growth hormone secretion in children and adolescents: can we make it with fewer samples?

Authors:  A Christoforidis; P Triantafyllou; A Slavakis; G Katzos
Journal:  J Endocrinol Invest       Date:  2013-07-23       Impact factor: 4.256

3.  Correlation of fl/d3 polymorphism of growth hormone receptor with the first- and second-year response to recombinant human growth hormone therapy in pre-pubertal Greek children with idiopathic isolated growth hormone deficiency.

Authors:  G Vassiliou; I Rousso; G Katzos; N Vavatsi-Christaki; G Tzimagiorgis
Journal:  J Endocrinol Invest       Date:  2010-09-17       Impact factor: 4.256

4.  Vasculometabolic effects in patients with congenital growth hormone deficiency with and without GH replacement therapy during adulthood.

Authors:  Isabela Peixoto Biscotto; Valéria Aparecida Costa Hong; Rafael Loch Batista; Berenice Bilharinho Mendonca; Ivo Jorge Prado Arnhold; Luiz Aparecido Bortolotto; Luciani Renata Silveira Carvalho
Journal:  Pituitary       Date:  2020-10-24       Impact factor: 4.107

5.  Clonidine-stimulated growth hormone concentrations (cut-off values) measured by immunochemiluminescent assay (ICMA) in children and adolescents with short stature.

Authors:  Maria de Fátima Borges; Flávia Carolina Cândida Teixeira; Aline Karin Feltrin; Karina Alvarenga Ribeiro; Gabriel Antonio Nogueira Nascentes; Elisabete Aparecida Mantovani Rodrigues Resende; Beatriz Pires Ferreira; Adriana Paula Silva; Heloísa Marcelina Cunha Palhares
Journal:  Clinics (Sao Paulo)       Date:  2016-04       Impact factor: 2.365

6.  Diagnosis of Idiopathic GHD in Children Based on Response to rhGH Treatment: The Importance of GH Provocative Tests and IGF-1.

Authors:  João Soares Felício; Luísa Corrêa Janaú; Marcelle Alves Moraes; Nathalie Abdallah Zahalan; Fabrício de Souza Resende; Manuela Nascimento de Lemos; Norberto Jorge Kzan de Souza Neto; Isabela Imbelloni Farias de Franco; Loyane Tamyres Costa Leitão; Lilian de Souza d'Albuquerque Silva; Maria Clara Neres Iunes de Oliveira; Angélica Leite de Alcântara; Ana Carolina Contente Braga de Souza; Wanderson Maia da Silva; Márcia Costa Dos Santos; Natércia Neves Marques de Queiroz; Lorena Vilhena de Moraes; Antônio Bentes de Figueiredo; Ana Luiza Prieto Farinassi; Luciana Marques da Costa Farias; Danielle Dias da Silva; Karem Miléo Felício; João Felício Abrahão Neto
Journal:  Front Endocrinol (Lausanne)       Date:  2019-09-19       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.